HPV Associated Disorders Market Report 2026

The hpv associated disorders market size has grown strongly in recent years. It will grow from $22.13 billion in 2025 to $23.7 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to high prevalence of hpv infections, introduction of prophylactic hpv vaccines, growth in cervical cancer screening programs, increasing healthcare expenditure in oncology, rising public health awareness campaigns.

The hpv associated disorders market size is expected to see strong growth in the next few years. It will grow to $30.97 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to expansion of gender-neutral vaccination policies, advances in molecular diagnostics, increasing incidence of hpv-linked oropharyngeal cancers, improved access to healthcare in emerging economies, pipeline development of therapeutic hpv vaccines. Major trends in the forecast period include expansion of hpv vaccination programs, rising adoption of early screening and diagnostics, growing focus on non-invasive treatment options, increasing awareness of hpv-related cancers, shift toward combination prevention and treatment strategies.

The growing prevalence of HPV cases is anticipated to drive the expansion of the HPV-associated disorders market in the coming years. HPV-associated disorders encompass benign conditions such as verrucae vulgates and condylomas acuminata, as well as malignancies affecting the cervix, vulva, anus, and penis, along with anogenital warts, recurrent respiratory papillomatosis, and anogenital and oropharyngeal cancers. HPV infection remains widespread globally, particularly among women. For example, in June 2025, the Centers for Disease Control and Prevention, a US-based government agency, reported that in the United States, approximately 13,000 women are diagnosed with cervical cancer each year, with about 4,000 deaths occurring annually due to the disease. As a result, the rising number of HPV cases is contributing to the growth of the HPV-associated disorders market.

Major companies operating in the HPV-associated disorders market are introducing HPV vaccines to address HPV-related diseases. HPV vaccines are vital to public health as they help lower the incidence of HPV-associated conditions and support cervical cancer screening and prevention initiatives. For example, in January 2023, the Serum Institute of India, an India-based organization, launched CERVAVAC, the first indigenously developed human papillomavirus (HPV) vaccine designed to prevent cervical cancer in women. The vaccine utilizes L1 virus-like particles (VLPs) to trigger an immune response without causing infection, thereby effectively preparing the immune system to identify and fight HPV upon future exposure.

In July 2025, Biological E, an India-based vaccine and pharmaceutical manufacturer, entered into a licensing and technology transfer agreement with Recbio to broaden access to advanced preventive therapies. Through this collaboration, Biological E plans to manufacture and commercialize Recbio’s recombinant 9-valent HPV (HPV9) vaccine, strengthening its efforts to address HPV-associated disorders by expanding the availability of advanced HPV prevention solutions across global markets. Recbio is a China-based biopharmaceutical company engaged in the development of innovative vaccines and biotechnology products, including the HPV9 vaccine.

Major companies operating in the hpv associated disorders market are AstraZeneca plc, F. Hoffmann-La Roche Ltd, Biocon Ltd, GlaxoSmithKline plc, Merck & Co Inc., Pfizer Inc., Sanofi S. A., Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Bayer AG, Eisai Co. Ltd., Genentech Inc., MSD Pharmaceuticals, Seqirus, Bavarian Nordic, Serum Institute of India, Moderna Inc.

North America was the largest region in the HPV associated disorders market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hpv associated disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hpv associated disorders market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have created moderate challenges for the HPV associated disorders market by increasing costs of imported vaccines, diagnostic kits, and pharmaceutical raw materials used in prevention and treatment therapies. Higher duties have affected pricing and availability across prevention and treatment segments, with developing regions in Asia-Pacific, Latin America, and parts of Africa being more sensitive due to reliance on imports. However, tariffs have also encouraged local manufacturing, regional supply chain diversification, and domestic vaccine production, supporting long-term market resilience and self-sufficiency.

The hpv associated disorders market research report is one of a series of new reports that provides hpv associated disorders market statistics, including hpv associated disorders industry global market size, regional shares, competitors with a hpv associated disorders market share, detailed hpv associated disorders market segments, market trends and opportunities, and any further data you may need to thrive in the hpv associated disorders industry. This hpv associated disorders market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Human papillomavirus (HPV)-associated disorders are conditions caused by a virus that can lead to abnormal tissue growth, such as warts and other cellular abnormalities. These disorders are primarily transmitted through sexual activity or other forms of skin-to-skin contact. Vaccines, medications, and diagnostic measures can help protect against HPV types that are associated with HPV-related cancers.

The main indications of HPV-associated disorders include cervical intraepithelial neoplasia (CIN), cervical cancer, anal intraepithelial neoplasia (AIN), anal cancer, genital warts, and other indications. The cervical intraepithelial indication of HPV-associated disorders focuses on the prevention and treatment of cervical intraepithelial neoplasia. Cervical intraepithelial neoplasia (CIN) involves abnormal changes in the cells lining the cervix. Prevention and treatment therapies for HPV-associated disorders are available through hospital pharmacies, retail pharmacies, and online pharmacies.

The human papillomavirus-associated disorders market includes revenues earned by entities by plantar warts and flat warts. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.